Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

David Chiu, M.D.

David Chiu, M.D.

David Chiu, M.D.

Associate Member
Houston Methodist Research Institute

Medical Director, Eddy Scurlock Stroke Center,
Houston Methodist Hospital
Neurologist, Houston Methodist Neurological Institute
Professor of Neurology 
Weill Cornell Medical College of Cornell University

E-mail: dchiu@houstonmethodist.org
Phone: 713-441-5066
Fax: 713-793-7019


M.D.   Yale University School of Medicine
B.S.   Yale University, summa cum laude Phi Beta Kappa (Electrical Engineering)

Postdoctoral Training

Fellowship in Cerebrovascular Disease, University of Texas at Houston School of Medicine
Residency in Neurology, University of California at San Francisco School of Medicine
Internship in Internal Medicine, University of California at San Francisco School of Medicine



David Chiu, M.D. is medical director of the Houston Methodist Eddy Scurlock Stroke Center in Houston and neurologist at the Houston Methodist Neurological Institute. He serves on the board of directors for the American Heart Association and is an active member of the American Academy of Neurology, American Heart Association Stroke Council, Texas Medical Association and Harris County Medical Association. He is also a reviewer for Stroke and Journal of Neurology, Neurosurgery and Psychiatry.

Dr. Chiu is associate professor of clinical neurology at the Weill Medical College of Cornell University He received his M.D. from Yale University School of Medicine. He completed his residency in neurology at the University of California at San Francisco and his fellowship in cerebrovascular disease at University of Texas at Houston School of Medicine.

Description of Research

Dr. Chiu has an active clinical practice that benefits from extensive translational research. His research interests lie in extending the time and quality of life for stroke patients, acute stroke treatment, and stroke prevention in those who have experienced TIA and stroke.

Recent Publications

Brott TG et al. and CREST Investigators. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 363:11-23 (2010).

Chiu D, Peterson L, Elkind MSV, Rosand J, Gerber LM, Silverstein MD. Glycine Antagonist in Neuroprotection (GAIN) Americas Trial Investigators. Comparison of outcomes after intracerebral hemorrhage and ischemic stroke. J Stroke Cerebrovasc Dis. 19:225-229 (2010).

The Ancrod Stroke Program Investigators. Levy DE, del Zoppo GJ, Demaerschalk BM, Demchuk AM, Diener HC, Howard G, Kaste M, Pancioli AM, Ringelstein EB, Spatareanu C, Wasiewski WW. Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 hours of stroke onset in the ancrod stroke program. Stroke. 40:3796-3803 (2009).

Zivin JA et al. and NeuroThera Effectiveness and Safety Trial-2 Investigators. Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. Stroke. 40:1359-1364 (2009).

Censullo J, Chiu D. Comprehensive stroke center quality metrics. Crit Pathways in Cardiol. 7:178-184 (2008).

SSYLVIA Study Investigators. Stenting of symptomatic atherosclerotic lesions in the vertebral or intracranial arteries (SSYLVIA): study results. Stroke. 35:1388-1392 (2004).